Interaction between MyRIP and the actin cytoskeleton regulates Weibel-Palade body trafficking and exocytosis. by Conte, IL et al.
RESEARCH ARTICLE
Interaction between MyRIP and the actin cytoskeleton regulates
Weibel–Palade body trafficking and exocytosis
Ianina L. Conte1,¶, Nicola Hellen2,*,¶, Ruben Bierings2,‡, Gregory I. Mashanov2, Jean-Baptiste Manneville3,
Nikolai I. Kiskin2, Matthew J. Hannah2,§, Justin E. Molloy2 and Tom Carter1,**
ABSTRACT
Weibel–Palade body (WPB)–actin interactions are essential for the
trafficking and secretion of von Willebrand factor; however, the
molecular basis for this interaction remains poorly defined. Myosin Va
(MyoVa or MYO5A) is recruited to WPBs by a Rab27A–MyRIP
complex and is thought to be the prime mediator of actin binding, but
direct MyRIP–actin interactions can also occur. To evaluate the
specific contribution of MyRIP–actin and MyRIP–MyoVa binding in
WPB trafficking and Ca2+-driven exocytosis, we used EGFP–MyRIP
point mutants with disrupted MyoVa and/or actin binding and high-
speed live-cell fluorescencemicroscopy.We now show that the ability
of MyRIP to restrict WPB movement depends upon its actin-binding
rather than its MyoVa-binding properties.We also show that, although
the role of MyRIP in Ca2+-driven exocytosis requires bothMyoVa- and
actin-binding potential, it is the latter that plays a dominant role. In view
of these results and together with the analysis of actin disruption or
stabilisation experiments, we propose that the role of MyRIP in
regulatingWPB trafficking and exocytosis is mediated largely through
its interaction with actin rather than with MyoVa.
KEY WORDS: Actin, Exocytosis, MyRIP, Myosin Va, Weibel–Palade
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INTRODUCTION
Weibel–Palade bodies (WPBs) are endothelial cell secretory granules
containing the adhesive glycoprotein von Willebrand factor (VWF).
VWF secretion is triggered by physico-mechanical and chemical
signals that increase intracellular free Ca2+ ([Ca2+]i) or cAMP
concentrations (Rondaij et al., 2006b). Mutations in VWF that result
in a qualitative or quantitative defect in function cause a family of
bleeding disorders collectively called vonWillebrand disease (Sadler
et al., 2006). Molecular defects affecting the trafficking or exocytosis
of WPBs can also give rise to alterations in circulating VWF and
cause bleeding disorders (van Loon et al., 2010; Zhu et al., 2014).
Trafficking and exocytosis of WPBs depend on the interplay
between microtubule transport and actin cytoskeleton tethering
(Manneville et al., 2003; Rojo Pulido et al., 2011; Rondaij et al.,
2006a; Vischer et al., 2000). WPBmovements on microtubules are
reduced through interactions with actin (Manneville et al., 2003),
which might help prevent untimely WPB exocytosis, allowing
VWF multimerization to proceed to its biologically more potent
high-molecular-mass form (Nightingale et al., 2009). However,
the precise molecular basis for WPB–actin interactions remain
poorly defined.
Specialised secretory cells express one or more of a subgroup of
small GTPases called ‘secretory Rabs’. These Rabs localise to the
secretory granule membrane and recruit soluble effector molecules
to regulate granule interactions with the cytoskeleton and the plasma
membrane during trafficking and exocytosis (Fukuda, 2008). WPBs
recruit the secretory Rabs, Rab27A and Rab3A, Rab3B and Rab3D,
and the effectors MyRIP, Munc13-4 (also known as UNC13D) and
Slp4 isoform a (Slp4-a; also known as SYTL4-a) (Bierings et al.,
2012; Nightingale et al., 2009; Zografou et al., 2012). The current
model places the molecular motor myosin Va (MyoVa or MYO5A)
as the primary link mediating WPB binding to actin, with MyoVa
being recruited to the granule through the Rab27A-specific effector
MyRIP (Rojo Pulido et al., 2011). However, it has been reported
that MyRIP can also bind actin directly through a C-terminal actin-
binding motif, similarly to the MyRIP-related protein melanophilin
(Waselle et al., 2003). Direct MyRIP–actin interaction has been
reported to play a role in regulating secretory granule trafficking and
exocytosis in endocrine and neuroendocrine cells (Huet et al., 2012;
Waselle et al., 2003); however, its contribution to WPB trafficking
and exocytosis has not yet been explored. To address this, we used
total internal reflection fluorescence microscopy (TIRFM) and
single-particle tracking to analyse the effect of MyRIP mutants with
disruptedMyoVa and/or actin-binding.We demonstrate that the role
of MyRIP can be only partly accounted for by its recruitment of
MyoVa, and thatMyRIP–actin interactions play a prominent role for
both trafficking and exocytosis.
RESULTS
Ca2+-driven WPB exocytosis after actin disruption or
stabilisation
To directly assess the effect of actin disruption on the kinetics of
Ca2+-driven WPB exocytosis, we used live-cell imaging of human
umbilical vein endothelial cells (HUVECs) expressing the WPB-
specific luminal marker EGFP-tagged VWF propolypeptide
(VWFpp–EGFP) (Hannah et al., 2005), which does not directly
interfere with interactions between WPBs and cytoskeletal
components or plasma membrane during exocytosis. Actin was
disrupted by cytochalasin D treatment (Fig. 1A) prior to stimulation
with ionomycin, andWPB fusion events plotted cumulatively as the
percentage of WPBs fused in each cell against time as previously
described (Hewlett et al., 2011) (Fig. 1Bi). The effect of actin
disruption was subtle: there was no significant change in the initial
delay or the mean maximal rate ofWPB fusion (Fig. 1Bii); however,Received 5 August 2015; Accepted 3 December 2015
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Fig. 1Bi shows that, shortly after stimulation (1–3 s), the rate of
WPB fusion in treated cells was slightly greater than in control cells.
This initial increased rate might account for the small, but
significant, increase in the overall number of fusion events
observed in treated cells (Fig. 1Bi,ii), and was mirrored by a
significant increase in stimulated, but not unstimulated (basal),
VWFpp secretion (Fig. 1C). These results show that the net effect of
actin cytoskeleton is to prevent Ca2+-driven WPB secretion.
To examine the role of actin dynamics in WPB exocytosis, we
stabilized actin filaments using the cyclic peptide jasplakinolide. To
determine an effective concentration of jasplakinolide, we monitored
the displacement of Rhodamine–phalloidin fluorescence by this
peptide, to confirm binding to F-actin, and used expressed YFP–actin
to visualise the actin cytoskeleton and cell morphology. Partial or
complete phalloidin displacement was seen at ≥100–350 nM
jasplakinolide (20 min) (Fig. 2Ai,ii; Fig. S1); however, a profound
disruption of the actin cytoskeleton and cell morphology was
observed at concentrations ≥1 µM (Fig. S1). Based on this, we used
100–500 nM jasplakinolide, and found no inhibition of Ca2+-evoked
VWF (Fig. 2Bi) or VWFpp (Fig. 2Bii) secretion. To examine this
further, we expressed an mCherry-tagged actin V159N mutant that
has previously been shown to stabilise F-actin (Posern et al., 2004).
BothWTandV159N actins localised to stress fibres and cortical actin
with no visible disruption to cell morphology (Fig. 2Ci,ii). Under
these conditions, neither the kinetics or extent of WPB fusion
(Fig. 2Di,ii), or VWFpp–EGFP secretion (Fig. 2E) were significantly
altered, suggesting that acute actin remodelling is not required for
regulating Ca2+-driven WPB exocytosis. Because jasplakinolide-
mediated disruption of actin dynamics has been reported to perturb
MyoVa-driven organelle transport (Semenova et al., 2008), the data
in Fig. 2 suggest that the reported role of MyoVa in WPB exocytosis
(Rojo Pulido et al., 2011) might reflect an effect on WPB docking or
fusion rather than movement on the actin cytoskeleton.
MyRIP–actin binding regulates WPB trafficking
In order to better understand the molecular interactions that regulate
the motion of WPBs through the actin-rich layer, we focused our
attention onMyRIP. MyRIP has an N-terminal domain that allows it
to interact with Rab27A (Fukuda and Kuroda, 2002) and be
recruited to WPBs (Nightingale et al., 2009) (Fig. 3A, top diagram).
This domain is followed by a central myosin-binding domain and a
C-terminal actin-binding domain. Although MyRIP can bind to
both MyoVa and MyoVIIa (Fukuda and Kuroda, 2002), we did not
detect endogenous MyoVIIa [by quantitative real-time PCR
(qPCR), western blotting or immunocytochemistry] in the
HUVEC cultures used here (data not shown) and therefore
concentrated on the MyoVa- and actin-binding properties of
MyRIP. To examine their individual contributions, we generated
EGFP-tagged MyRIP mutants: MyRIP A751P, which has been
previously shown to be defective in MyoVa recruitment and
activation in melanosomes (Ramalho et al., 2009), MyRIP R774A,
R777A, R778A, R779A (from now on referred to as MyRIP 4A)
that is defective in actin binding (Waselle et al., 2003), and the
combined mutant MyRIP A751P 4A, designed to disrupt both
MyoVa and actin interactions (Fig. 3B–D). We chose this approach
rather than the previously used C-terminal truncations to avoid
confounding results due to the presence of specific residues crucial
for both MyoVa- and actin-binding within this region (Ramalho
et al., 2009). All MyRIP constructs retained the Rab27A-binding
domain and were recruited to WPBs (Fig. 3A–D). To confirm that
specific disruption of the actin-binding region within the C-terminal
domain did not prevent MyoVa recruitment to the WPB, we
Fig. 1. The actin cytoskeleton limits Ca2+-driven WPB
exocytosis. (A) Rhodamine (Rh)–phalloidin labelling of
HUVECs after a 20-min incubation with vehicle (0.1%
DMSO) (i), or 1 µM cytochalasin D (Cyto-D) (ii). Scale bars:
10 µm. (Bi) Cumulative plots of the total number of WPB
fusion events detected during ionomycin stimulation (1 µM,
applied at t=0 s) of VWFpp–EGFP-expressing HUVECs
pre-treated for 20 min with vehicle [0.1% DMSO, no
cytochalasin D (−Cyto-D), black, n=954] or 1 µM Cyto-D
(+Cyto-D; grey, n=934). Data are scaled to the mean fraction
of fluorescent WPBs that underwent fusion in each condition
(−Cyto-D, 61.1±2.6%, n=19 cells; +Cyto-D, 71.0± 3.3%,
n=23 cells; mean±s.e.m.). (Bii) Summaryof themean±s.e.m.
delay, maximum rate and percentage of fluorescent WPBs
exocytosed in control (black, n=19) and Cyto-D-treated
(grey, n=23) cells. *P=0.013, t-test. (C) Ionomycin-stimulated
secretion of endogenous VWFpp in control; −Cyto-D (black)
or +Cyto-D (grey) cells. Plots show data pooled from
three independent experiments performed in triplicate
(mean±s.e.m., n=9 replicates). *Adjusted P=0.011, ANOVA,
Tukey multiple comparisons test.
593
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 592-603 doi:10.1242/jcs.178285
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
examined the localisation of endogenousMyoVa in cells expressing
EGFP–MyRIP A4 (Fig. 3E,F). No evidence for loss or depletion of
endogenous MyoVa immunoreactivity from WPBs was seen.
To test whether the A751P mutation perturbed the actin binding
properties of MyRIP we determined the off-rates for the MyRIP-
actin interaction by high-resolution single molecule imaging and
single molecule dwell time analysis in live cells. The data showed
that cytosolic MyRIP WT and MyRIP A751P bind transiently to
cortical actin and stress fibres (Fig. 4Ai–iii,Bi–iii; Movies 1, 2) with
similar off-rates of 14.7 s−1 and 16.1 s−1, respectively (Fig. 4Ei,ii).
In contrast, actin binding was abolished for MyRIP 4A and MyRIP
A751P 4A (Fig. 4Ci–iii,Di–iii; Movies 3, 4). This argues that, in the
free state, MyRIP binding to actin is independent of the ability of
MyRIP to recruit MyoVa.
Fig. 2. Actin remodelling is not required for Ca2+-driven
WPB exocytosis. (A) Effect of jasplakinolide on actin
cytoskeleton and cell morphology. Images show the effect
of a 20-min incubation with vehicle (i) or 0.35 µM
jasplakinolide (Jas, ii) on the actin cytoskeleton and cell
morphology visualised by expression of YFP–actin (green
in colour merged images). Competitive binding of
jasplakinolide to actin is manifested by the displacement of
Rhodamine–phalloidin staining (red in colour merged
images). Scale bars: 10 µm. (B) Effect of a 20-min pre-
treatment of HUVECs with jasplakinolide (at the indicated
concentrations) on ionomycin-evoked (1 µM) VWF (i) or
VWFpp (ii) secretion. Stimulation was for 10 min in the
continued presence of vehicle or jasplakinolide.
Experiments shown are representative of thre independent
experiments performed in triplicate (mean±s.e.m.).
(C) Images of single HUVECs 24 h after nucleofection with
mCherry–actin WT (red; anti-RFP antibody) (i), or
mCherry–actin V159N (red; anti-RFP antibody) (ii), and
counterstained with Alexa-Fluor-488–phalloidin (green).
Regions indicated by white boxes are shown as greyscale
inserts. Arrowheads indicate colocalisation of RFP
fluorescence with actin filaments. Scale bars: 10 µm.
(Di) Cumulative plots of the total number of WPB fusion
events detected during ionomycin stimulation (as in
Fig. 1Bi) of HUVECs co-expressing VWFpp–EGFP and
mCherry–actin WT (black, n=1038), or mCherry–actin
V159N (grey, n=999). Data are scaled to the mean fraction
of fluorescent WPBs that underwent fusion in each case
(actinWT, 62.8±2.9%, n=21 cells; actin V159N, 60.4±3.0%,
n=21 cells; mean±s.e.m.). (Dii) Summary of the delay,
maximum rate and percentage of fluorescent WPBs
exocytosed for cells expressing mCherry–actin WT (black;
mean±s.e.m., n=21) or mCherry-actin V159N (grey;
mean±s.e.m., n=21). (E) Ionomycin-stimulated secretion
of VWFpp–EGFP in mCherry–actin WT (black) or
mCherry–actin V159N (grey) co-expressing cells. Plots
show data pooled from three independent experiments
performed in triplicate (mean±s.e.m.).
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Analysis of the movements of WPBs overexpressing wild-type
EGFP–MyRIP (EGFP–MyRIP WT) showed that there was a
reduction in the fraction of WPBs exhibiting long-range
movements, conceivably due to an increased interaction with
F-actin that counteracts WPB motions on microtubules (Manneville
et al., 2003). These WPBs also showed a reduction in their
maximum displacement and velocity compared to those in cells
expressing theWPB luminal marker VWFpp–EGFP (Fig. 5Ai,ii,B).
Consistent with dwell time analysis, we found that WPBs carrying
MyRIPA751P behaved identically to those carrying MyRIP WT
(Fig. 5Aiii,B) suggesting that the brake that MyRIP exerts on the
movement of WPBs is not mediated by MyoVa. Conversely, a
Fig. 3. Subcellular localisation of EGFP–MyRIP
mutants in HUVECs – mutation of the actin-
binding region does not perturb endogenous
MyoVa recruitment to WPBs. (A) Top, schematic
structure of human MyRIP domains and position
of the mutated amino acids. Below, confocal
immunofluorescence image of a single HUVEC
expressing EGFP–MyRIP WT and labelled with
phalloidin (red) and specific antibodies against
EGFP (green) and VWF (blue). Regions indicated
by white boxes are shown as greyscale inserts.
(B–D) As for A but for cells expressing EGFP–
MyRIP A751P (B), EGFP–MyRIP 4A (C) and
EGFP–MyRIP A751P 4A (D). (E,F) Confocal
immunofluorescence images of single HUVECs
expressing EGFP–MyRIP WT (E) or EGFP–
MyRIP 4A (F), and labelled with specific antibodies
to EGFP (green) and MyoVa (red). Greyscale
images below show, on the same scale,
endogenousMyoVa immunoreactivity from regions
indicated in the MyRIP-expressing (i) and non-
expressing (ii) cells. Scale bars: 10 µm.
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higher proportion of WPBs carrying MyRIP 4A showed longer
trajectories and faster movements (Fig. 5Aiv,B), and no additional
increases were seen for WPBs carrying the combined mutant
(Fig. 5Av,B). A similar phenotype was seen for VWFpp–EGFP-
labelled WPBs after depletion of endogenous MyRIP by small
interfering RNA (siRNA) (Fig. S2B), strongly indicating that
MyRIP–actin interactions are the ones primarily responsible for the
role of MyRIP in WPB trafficking. In addition, rapid long-range
WPB movements in cells expressing MyRIP WT, MyRIP 4A or
MyRIPA751P 4Awere abolished by nocodozole treatment (Fig. 6),
confirming that these take place along microtubules (Manneville
et al., 2003).
Fig. 4. Actin-binding properties of EGFP–MyRIP mutants. (Ai–Di) Images from dual colour TIRF movies of live HUVECs co-expressing EGFP–MyRIP
constructs (green) and TagRFP–actin (red) showing MyRIP WT (Ai) and MyRIP A751P (Bi), but not MyRIP 4A (Ci) or MyRIP A751P 4A (Di) decorating cortical
actin and stress fibres. Images are averages of 134 to 222 consecutive frames acquired at 33 frames/s. Scale bars: 20 µm. Regions indicated by white boxes
in Ai–Di are shown in greyscale below the colour merged images. Dual-colour video clips of a small sub-region of each cell are shown in Movies 1–4.
(Aii–Dii) Representative examples of single-colour TIRF images of live HUVECs expressing MyRIP WT, MyRIP A751P, MyRIP 4A or MyRIP A751P 4A. Images
are averages of 401–900 consecutive frames taken from videos acquired at 50 frames/s. To minimise false detection events during automatic single fluorophore
detection and analysis, cells expressing EGFP–MyRIPmutants containing few or noWPBswere selected for recording. (Aiii–Diii) White tracks show the detected
trajectories of single EGFP fluorophores for the cells in Aii–Dii (Aiii, 7731 detected objects; Biii, 6448 objects, Ciii, 54 objects; Dii, 89 objects). Scale bars: 20 µm.
(E) Lifetime distributions for single fluorophore interaction of EGFP–MyRIP WT (i, n=12,703 objects from 16 cells) or EGFP–MyRIP A751P (ii, n=12,461 objects
from 10 cells) and actin derived from experiments illustrated in Aii,iii or Bii,iii, respectively. Red lines showexponential fits (i, R=0.98; ii, R=0.99) to the distributions,
and the off-rates determined from the fits are shown on the plots. Events with durations less than 200 ms were excluded to avoid short-lived ‘false’ events (see
Materials and Methods).
596
RESEARCH ARTICLE Journal of Cell Science (2016) 129, 592-603 doi:10.1242/jcs.178285
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
We next analysed short-range WPB movements. WPB–actin
interactions limit the movement of the organelle and can be
analysed by determining the magnitude of short-range x-y
displacements, the ‘cage radius’ (Manneville et al., 2003). The
stronger the actin interaction, the more restricted WPB movements
become hence reducing the cage radius. In agreement with the
analysis of long-range movements, we found that, for WPBs in cells
expressing MyRIP WT or MyRIP A751P, the cage radius was
smaller than for cells expressing VWFpp–EGFP, whereas the cage
radius was increased with MyRIP 4A or MyRIP A751P 4A
(Fig. 5C).
MyRIP–actin interaction prevents WPB exocytosis
We next evaluated the effect of the EGFP–MyRIP mutants on
Ca2+-driven WPB exocytosis. To directly compare the secretory
responses between the different EGFP–MyRIP mutants, we
selected cells that contained approximately equal numbers of
fluorescent WPBs and which had similar WPB-associated
EGFP fluorescence intensities (i.e. WPB EGFP–MyRIP
mutant concentrations, see also Materials and Methods)
(Fig. 7A). In this way, we aimed to minimise the effect on
secretion of cell-to-cell variations in the amounts of each
transgene on WPBs. Under these conditions, and consistent
with previous findings (Bierings et al., 2012), expression of
MyRIP WT completely inhibited WPB fusion (Fig. 7B).
Expression of MyRIP A751P resulted instead, in a reduced
inhibition of exocytosis, albeit with a slow onset compared to
VWFpp–EGFP-expressing cells (delay 11.82± 4.55 s, n=28
cells versus 1.72±0.13 s, n=19 cells, respectively, P=0.005, mean
±s.e.m.) (Fig. 7B). Strikingly, with MyRIP 4A and MyRIP A751P
4A, WPB fusion events increased to ∼75% of those seen in
VWFpp–EGFP-expressing cells (Fig. 7B), and the delays were not
significantly different from those in cells expressing VWFpp–
EGFP (5.05±0.97 s, n=23, P=0.75; 4.03± 0.68 s, n=19, P=0.94,
respectively). A recovery of WPB exocytosis to levels seen with
VWFpp–EGFP was not expected because overexpression of
MyRIP might displace other endogenous positive regulators of
WPB exocytosis (e.g. Slp4-a or Munc13-4) that compete for
binding to active Rab27A (Bierings et al., 2012; Zografou et al.,
2012). To analyse further the contribution of the actin-binding
property of MyRIP, we disrupted the actin cytoskeleton
(cytochalasin D, 1 µM, 20 min) and determined the WPB
secretory kinetics in cells expressing MyRIP WT and MyRIP
A751P (Fig. 7B). Consistent with a prominent role of MyRIP–
actin binding, we observed exocytosis of MyRIP-WT-expressing
WPBs (delay 8.54±1.78 s, n=13), although the extent of
exocytosis (29.3±4.0% of fluorescent WPBs, n=8) failed to
reach that of MyRIP 4A (46±3.2% of fluorescent WPBs, n=23)
(Fig. 7B). For MyRIP A751P, we found a significant decrease in
the delay in exocytosis, to 4.14±1.26 s (n=9), that was now
no different from that of WPBs expressing VWFpp–EGFP
(P=0.99), MyRIP 4A (P=0.99) or MyRIP A751 4A (P=0.99).
There was a significant increase in the extent of exocytosis from
16.4±2.4% (n=23) to 41.2±3.8% (n=19) of fluorescent WPBs
(P=0.0001) (Fig. 7B), to a level now similar to that seen with
cells expressing MyRIP 4A (P=0.90) or MyRIP A751P 4A
(P=0.96). Finally, we determined the effect of actin disruption on
Ca2+-driven VWFpp secretion in cells depleted of endogenous
MyRIP by siRNA (Fig. S2C). Interestingly, although we did
not observe a significant increase in VWFpp secretion upon
MyRIP knockdown using ionomycin, we found a significant
increase in VWFpp secretion in both cells treated with control
siRNA siControl and siRNA against MyRIP (siMyRIP) upon
cytochalasin D treatment. These results indicate that MyRIP
regulates WPB exocytosis through its direct interaction with actin
Fig. 5. MyRIP–actin interaction regulates WPB trafficking.
(A) Representative x-y trajectories of individual WPBs in single HUVECs
expressing VWFpp–EGFP (i), EGFP–MyRIP WT (ii), EGFP–MyRIP A751P
(iii), EGFP–MyRIP 4A (iv) or EGFP–MyRIP A751P 4A (v). Trajectories were
determined here and elsewhere fromTIRFM videos using the ASPT function of
GMimPro software (see Materials and Methods). The number of cells imaged
and trajectories detected were: VWFpp, n=15 cells, 3890 trajectories; MyRIP
WT, n=11 cells, 2978 trajectories; MyRIPA751P, n=13 cells, 1278 trajectories;
MyRIP 4A, n=8 cells, 1862 trajectories; MyRIP A751P 4A, n=11 cells, 1310
trajectories. (B,C) Mean±s.e.m. parameters determined from detected
trajectories of long-range (Bi–iii) or short-range (C) movements of WPBs in
HUVECs expressing EGFP fusion proteins of VWFpp, MyRIP WT and MyRIP
mutants as indicated. Number of WPBs analysed for short-range movements
were: VWFpp, n=277; MyRIP WT, n=86; MyRIP A751P, n=242; MyRIP 4A,
n=250; MyRIP A751P 4A, n=387. P values are with respect to VWFpp–EGFP
(one-way ANOVA using Tukey multiple comparisons test).
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and MyoVa, and highlight the important point that other
mechanisms involving the actin cytoskeleton must also play a
role (see Discussion).
DISCUSSION
The actin cytoskeleton plays multiple roles in the regulation of
secretory granule trafficking and exocytosis (Porat-Shliom et al.,
Fig. 6. Microtubule disruption abolishes long-range movements of WPBs carrying actin-binding-defective EGFP–MyRIP mutants. (Ai–Ci)
Representative confocal immunofluorescence images of individual HUVECs expressing EGFP fusion proteins of MyRIPWT (Ai), MyRIP 4A (Bi) or MyRIPA751P
4A (Ci) exposed to vehicle (0.1% DMSO, 20 min: −Noco) and labelled with specific antibodies to EGFP (green), α-tubulin (red) and actin (phalloidin; blue). Scale
bars: 20 µm. (Aii–Cii) Representative examples of the x-y trajectories of individual WPBs in control (−Noco) HUVECs expressing EGFP fusion proteins of MyRIP
WT (Aii), MyRIP 4A (Bii) or MyRIPA751P 4A (Cii). Number of cells imaged and trajectories detectedwere: MyRIPWT, n=7 cells, 1007 trajectories; MyRIP 4A, n=3
cells, 448 trajectories; MyRIP A751P 4A, n=8 cells, 1667 trajectories. Scale bar: 10 µm for Aii-Cii (shown in Cii). (Aiii–Ciii) Representative confocal
immunofluorescence images of individual HUVECs expressing the same EGFP fusion proteins and stained as described in Ai–Ci, but after treatment with
nocodozole (1 µM, 20 min: +Noco). Scale bars: 20 µm. (Aiv–Civ) Representative examples of the x-y trajectories of individual WPBs in +Noco treated HUVECs
expressing EGFP fusion proteins of MyRIP WT (Aiv), MyRIP 4A (Biv) or MyRIP A751P 4A (Civ). Number of cells imaged and trajectories detected were: MyRIP
WT, n=3 cells, 497 trajectories; MyRIP 4A, n=7 cells, 125 trajectories; MyRIP A751P 4A, n=10 cells, 392 trajectories. Scale bar: 10 µm for Aiv-Civ (shown in Civ).
(Di–iii) Mean±s.e.m. values for the fraction of WPBs with movements greater than 3 µm in length (Di), maximum displacement from start of recording (Dii) and
maximum velocity (Diii) determined from the detected trajectories of the WPBs in control (−Noco) or nocodozole (+Noco) treated cells expressing the MyRIP
fusion proteins as indicated. Number of cells imaged and trajectories detected in−Noco and +Noco treated cells are as described above.P values were calculated
with a one-way ANOVA using Tukey multiple comparisons test.
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2013). Our previous work has shown that WPB–actin interactions
regulate trafficking of this organelle close to the plasma membrane
(Manneville et al., 2003), and here we have examined in more detail
the molecular basis for this interaction.
Pharmacological disruption of the actin cytoskeleton produced a
small, but statistically significant, increase in both WPB exocytosis
and VWFpp secretion. These results are consistent with a model
in which one of the roles of the actin cytoskeleton is to regulate
Ca2+-stimulated WPB exocytosis. In addition, our new kinetic data
suggest that upon treatment with cytochalasin D more WPBs
became available for early release, contributing to the increased rate
of WPBs fusing in the first 1–3 s. The physiological relevance of
initially limiting the rate of exocytosis remains unclear, however, it
might simply reflect the response time of the cellular machinery to
the stimulus used. The failure of actin disruption to change the onset
of exocytosis shows that there is a small pool of WPBs that have
already overcome the actin hurdle and are ready to fuse, suggesting
that the final steps in fusion are independent of actin. Consistent
with this, failure of actin stabilisation to alter Ca2+-driven VWF
secretion confirmed that acute actin re-modelling is not essential for
this process.
Our findings agree with a previous study of hormone- and
Ca2+-driven VWF secretion (Vischer et al., 2000), but differ in
several respects from results obtained with the non-physiological
secretagogue, phorbol myristate acetate (PMA) (Nightingale et al.,
2009, 2011). During PMA stimulation, and in line with our
observations, actin disruption results in an increase in the number of
WPB fusion events. However, in contrast to our data and that of
Vischer et al., 2000, PMA-induced VWF secretion is completely
abolished (Nightingale et al., 2009). In the latter study, it was
proposed that, in addition to acting as a barrier to WPB fusion, actin
participates in the expulsion of VWF from WPBs through the
formation and contraction of an actomyosin ring around the post-
fusion WPB (Nightingale et al., 2011). However, recent analysis
shows that this actomyosin mechanism does not contribute to Ca2+-
drivenWPB exocytosis and VWF secretion (Conte et al., 2015). We
suggest that a main function of the actin cytoskeleton during Ca2+-
driven exocytosis is to prevent rather than promote WPB exocytosis
by restraining WPBs, limiting their access to the plasma membrane
for fusion.
We next focused on the molecular components of the WPB that
contribute to the interaction with actin. MyRIP has been described
as a negative regulator of WPB exocytosis through its capacity to
recruit MyoVa to clamp WPBs in the peripheral cortical actin,
preventing exocytosis (Nightingale et al., 2009). However, studies
in other cell types suggest that direct MyRIP–actin interaction might
also play an important role in the regulation of secretory granule
trafficking and exocytosis (Desnos et al., 2003; Huet et al., 2012;
Waselle et al., 2003). The melanocyte Rab27A–MyoVa adapter
protein melanophilin is closely related to MyRIP (Fukuda, 2008).
Melanophilin binds MyoVa through several distinct regions
including a MyoVa-globular-tail-binding domain (GTBD), a
MyoVa-exon-F-binding domain (EFBD) and an amphipathic
helix (MMAH) region towards the C-terminal end of the protein
(Hume et al., 2006). The GTBD is not conserved in MyRIP, and
mutagenesis studies have shown that only the MMAH region is
essential for MyoVa binding by MyRIP, whereas other regions
including the EFBD are non-essential for this interaction (Ramalho
et al., 2009). Deletion or specific single point mutations within the
MMAH effectively disrupt MyoVa binding and result in a failure of
the mutant MyRIPs to rescue melanosome transport defects in
melonophilin-null melanocytes (Ramalho et al., 2009). Because the
actin-binding region of MyRIP is also located in the C-terminus
of the protein (Kuroda et al., 2003; Waselle et al., 2003), a simple
C-terminal truncation will disrupt both actin and MyoVa binding,
complicating the analysis of the contributions of actin and/or
MyoVa binding in MyRIP function. In this light, we chose to make
a single point mutation in the MMAH of MyRIP that strongly
disrupts MyoVa binding (Ramalho et al., 2009) while retaining the
crucial actin-binding motif. Single-molecule imaging of the MyRIP
mutants we generated showed that whereas the point mutation in the
MMAH of MyRIP (MyRIP A751P) did not affect MyRIP binding
to actin, the mutations on the actin-binding domain (MyRIP 4A) had
a drastic effect, completely abolishing MyRIP–actin interactions.
Taken together with the observation that mutations of the actin-
binding domain did not perturb MyoVa recruitment to WPBs
(Fig. 3F,G), our data strongly indicate that MyRIP binding to actin is
independent of the ability of MyRIP to recruit MyoVa.
Our single-molecule dwell time analysis in live HUVECs showed
that cytosolic MyRIP interacts weakly with actin, with a fast off rate
Fig. 7. MyRIP-actin interaction regulates WPB exocytosis. (A) Mean±
s.e.m. for the WPB-associated EGFP fluorescence intensity (solid circles) and
numbers of fluorescent WPBs (solid squares) in cells expressing MyRIP WT
(black, n=7), MyRIP A751P (red, n=28), MyRIP 4A (blue, n=23) and MyRIP
A751P 4A (green, n=19). Open symbols show data for cells pre-treated with
cytochalasin D (1 µM, 20 min). (B) Cumulative plots of the total number ofWPB
fusion events detected during ionomycin stimulation (1 µM, applied at t=0 s) for
HUVECs expressing VWFpp–EGFP (grey dotted line, n=19 cells, 1074 fusion
events, delay to first fusion event, 1.72±0.13 s; mean±s.e.m.), MyRIP WT (no
trace, n=7, 0, 0 s), MyRIP A751P (red symbols, n=28, 219, 11.82±4.56 s),
MyRIP 4A (blue symbols, n=23, 556, 5.05±0.97 s), MyRIP A751P 4A (green
symbols, n=19, 557, 4.03±0.68 s). Dashed lines show data in cells treated with
cytochalasin D (+CytoD, 1 µM, 20 min) expressing MyRIP WT (black dashed
line, n=14, 91, 8.54±1.78 s) or MyRIP A751P (red dashed line, n=19, 320,
4.44±0.98 s). Delays were compared using ANOVAmultiple comparisons with
multiplicity adjusted; P-values are given in the main text. Data are scaled to the
mean fraction of fluorescent WPBs that underwent fusion in each condition
(VWFpp, 65.5±3.2%, n=19 cells; MyRIP WT, 0%, n=7 cells; cytochalasin-D-
treated MyRIP WT, 23.2±1.7%, n=14 cells; MyRIP A751P, 17.6±3.4%, n=28
cells; cytochalasin-D-treated MyRIP A751P, 40.89±3.58%, n=19 cells; MyRIP
4A, 47.9±4.1%, n=23 cells; MyRIP A751P 4A, 50.1±4.1%, n=19 cells; mean
±s.e.m.).
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(Fig. 4E) that could provide a mechanism to allow free MyRIP to
diffuse and recycle to WPB-associated Rab27A. Indeed, increased
diffusion, due to weak actin binding of free ATP-loaded MyoVa,
has previously been suggested to be important for the efficient
recycling of that motor protein to new cargo (Thirumurugan et al.,
2006). Rab27A cycles on and off WPBs slowly (Bierings et al.,
2012), a process thought to be regulated by the slow GTP-GDP
exchange cycle for Rab27A (Kondo et al., 2006; Larijani et al.,
2003). Our preliminary observations using wholeWPB bleaching to
study the timecourse for cycling of EGFP–MyRIP onto the WPB,
suggest that once associated with endogenous (or exogenously
expressed) Rab27A, MyRIP becomes tightly bound (Fig. S3). The
slow cycling of MyRIP onto WPBs is no different from that of
Rab27A itself (Bierings et al., 2012), suggesting that it is governed
by the Rab27A GTP-GDP exchange cycle (Kondo et al., 2006;
Larijani et al., 2003). The slow cycling of MyRIP is likely to
account for its striking accumulation on WPBs, and, if the off rate
for the MyRIP–actin interaction remains weak when bound to
Rab27A, then concentrating many MyRIP molecules on the
organelle will tend to favour an increase in the avidity of the
MyRIP–actin interaction enhancing a tethering function. It is also
possible that the strength of individual interactions between MyRIP
and actin might increase whenMyRIP is incorporated into its cargo-
binding complex, as proposed for MyoVa (Thirumurugan et al.,
2006), and for EGFP–Rab27A–melanophilin complexes bound to
actin in vitro (Wu et al., 2006). Thus, weak actin binding in the free
state will prevent MyRIP sequestration onto actin and allow it to
accumulate on WPB–Rab27A and participate in clamping the
granule into the actin cytoskeleton.
Analysis of the mobility of WPBs overexpressing EGFP–MyRIP
WT revealed a drop in the proportion of WPBs with long
trajectories, arguably caused by increased interaction with F-actin
that counteracts WPB motions on microtubules (Manneville et al.,
2003). This interpretation is supported by a complete abolition of
long-range movements upon microtubule disruption (Fig. 6). This
behaviour did not change for WPBs carrying MyRIP A751P and
only when direct MyRIP–actin interactions were disrupted (MyRIP
4A) did we observe an increment in the proportion of WPBs with
long-range movements. In this respect, the actin-binding-deficient
mutant phenocopies the depletion of endogenous MyRIP.
Consistent with our findings, an increased proportion of secretory
granules with long trajectories has also been observed in
neuroendocrine cells subjected to MyRIP silencing, together with
an increment in secretory granule velocities (Huet et al., 2012). Our
kinetic analysis highlights the striking result that the role of MyRIP
in WPB trafficking is not mediated by MyoVa, instead, MyRIP–
actin interactions are the ones guiding the participation MyRIP in
WPB mobility. However, a role for MyoVa–actin binding or
transport in regulating WPB movements cannot be ruled out
because MyoVa might potentially be recruited to WPBs through
Rab27A–MyRIP-independent mechanisms (Lindsay et al., 2013;
Wollert et al., 2011). In this context, other MyoVa partners might
have a more prominent role in assisting the part that MyoVa plays in
the movement of WPBs. Potential partners include Rab3 isoforms
(Lindsay et al., 2013; Wollert et al., 2011), which are known to
localise to WPBs (Bierings et al., 2012; Karniguian et al., 1993;
Zografou et al., 2012). Moreover, a brain splice isoform of MyoVa
has also been shown to bind both Slp4-a and rabphilin-3A in
pancreatic β-cells (Brozzi et al., 2012a). Although this MyoVa
isoform was not detected in HUVECs (Rojo Pulido et al., 2011), it
only makes it more pressing to further our understanding on the
complex mechanisms of MyoVa recruitment to WPBs.
Using high-speed live-cell TIRFM imaging, we analysed the
effect of the expression of MyRIP mutants on Ca2+-driven WPB
exocytosis. In the wild-type state, endogenous MyRIP has to
compete for GTP-Rab27A with at least two other effectors, Slp4-a
andMunc13-4 (Bierings et al., 2012; Zografou et al., 2012). Both of
these effectors are positive regulators of WPB exocytosis, and Slp4-
a in particular can also bind GDP-Rab27A, potentially allowing it to
compete more effectively for Rab27A than MyRIP and Munc13-4
(Bierings et al., 2012). Competition between these different
effectors balances the forces promoting and preventing
exocytosis. In the wild-type state, the balance favours exocytosis
(Bierings et al., 2012). Overexpression of MyRIP tilts the balance
towards strong inhibition of secretion, through its ability to bind
actin and MyoVa, and also potentially by displacement of the
positive regulators Slp4-a and Munc13-4 from Rab27A. Being
aware of these issues, we minimised cell-to-cell variations in WPB-
associated MyRIP mutant concentrations by analysing cells with
similar numbers of WPBs and with similar mean WPB EGFP
fluorescence intensities (Fig. 7A,B). In this way, we hoped to
compare more objectively the impact of a specific MyRIP mutation
on WPB exocytosis kinetics. We found that specifically removing
the ability of MyRIP to bind actin largely abolished its inhibitory
effect, showing that direct actin binding underpins the negative
function ofMyRIP. Consistent with this, we found that disruption of
the actin cytoskeleton in cells expressingMyRIPA751P reduced the
delay and increased the extent of exocytosis to levels similar to those
forMyRIP 4A and the combined mutant. Taken together, our results
strongly support a model in which MyRIP–actin interactions play
the dominant role in the function of MyRIP.
However, the contribution of the MyRIP–MyoVa interaction we
observed in exocytosis (Fig. 7B), in contrast to trafficking (Fig. 5),
should not be overlooked. Previous studies have shown that
knockdown of MyoVa results in an increase in histamine-evoked
VWF secretion (Rojo Pulido et al., 2011), and consistent with this
we found that disruption of the MyoVa interaction with MyRIP,
using MyRIP A751P, resulted in the appearance of WPB fusion
events, albeit with a long delay and to a lesser extent compared to in
cells expressingMyRIP 4A. This observation, coupled with the lack
of effect of jasplakinolide on Ca2+-driven VWF secretion, suggest
that there is a role for MyoVa in a later step in WPB exocytosis.
Intriguingly, we found an increase in VWF secretion upon
cytochalasin D treatment in MyRIP-depleted cells, suggesting that
MyRIP–actin interactions are not solely responsible for preventing
WPB exocytosis. It is interesting to speculate that MyoVa might,
through alternative binding partners (see discussion above), provide
some measure of functional redundancy in the regulation of WPB–
actin interactions and exocytosis. Interestingly, MyoVa has been
shown to play a positive role in exocytosis in other cell types. Under
conditions of strong stimulation where [Ca2+]i is elevated to high
levels, calmodulin is known to dissociate from MyoVa IQ motifs
(Sellers et al., 2008). In neurons, syntaxin-1A can bind to
unoccupied MyoVa IQ motifs to promote assembly of the vesicle
fusion apparatus (Watanabe et al., 2005) and, although this
possibility has not been explored in endothelial cells, it is
tempting to speculate that syntaxins 2, 3 or 4, which have been
implicated in WPB exocytosis (Fu et al., 2005; van Breevoort et al.,
2014), might also bind unoccupied MyoVa IQ motifs to modulate
the function of the fusion apparatus.
In pancreatic β-cells, MyoVa recruitment by MyRIP only occurs
after triggering PKA activation through the cAMP pathway,
resulting in phosphorylation of rabphilin-3 (Brozzi et al., 2012b).
Although, we could not detect any rabphilin-3 in HUVECs (data not
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shown), it shares a similar structure to Slp4-a, which is
phosphorylated upon thrombin stimulation (van den Biggelaar
et al., 2014), raising the intriguing possibility that MyoVa is
recruited to WPBs in an activation-dependent fashion to regulate
fusion. Thus, the function ofMyoVamight not be as straightforward
as initially imagined, depending on its mode of recruitment and
activation in a space-and-time-appropriate manner.
Here, we have demonstrated that MyRIP directly mediates WPB
interactions with the cortical actin network. This action does not rule
out the proposed involvement of MyRIP in docking secretory
granules to the plasma membrane (Huet et al., 2012) and the
interaction of MyRIP with the exocyst complex (Goehring et al.,
2007), which might not have been affected owing to the retention of
the C-terminal domain, allowing the very pronounced recovery of
exocytosis upon removal of the MyRIP–actin clamp. Our data
suggest that trafficking and exocytosis of WPBs, which result from
the complex interplay of a cocktail of Rab GTPases, effectors and
other secretory mediators, can only begin to be understood by
careful analysis of the molecular contributions of the individual
components.
MATERIALS AND METHODS
Reagents
All reagents were from Sigma-Aldrich (Gillingham, UK) unless otherwise
stated. Fura-2/AM and Rhodamine or FITC-conjugated phalloidin were
from Life Technologies (Paisley, UK).
Tissue culture, RNAi knockdown, ELISAs and
immunocytochemistry
HUVECswere cultured and transfected as described previously (Erent et al.,
2007). Endogenous MyRIP was depleted by RNAi using specific
oligonucleotides (GE Healthcare, Little Chalfont, UK), and western blot
analysis was carried out as previously described (Bierings et al., 2012).
Biochemical secretion assays were carried out in release medium (serum-
free M199, HEPES; 10 mM, pH 7.4) at 37°C, and secreted VWF and
VWFpp were assayed by ELISA as described previously (Hewlett et al.,
2011). Immunocytochemistry was performed as described previously
(Bierings et al., 2012). Antibodies and dilutions used were as following:
mouse monoclonal anti-GFP antibody (clone 7.1 and 13.1, 1:500) from
Roche (Welwyn Garden City, UK), rabbit polyclonal anti-RFP antibody
(ab62341, 1:200) and goat polyclonal anti-MyRIP antibody (ab10149,
1:200) from Abcam (Cambridge, UK), rabbit polyclonal anti-VWF
antibody (A0082, 1:10,000) from Dako (Ely, UK), sheep polyclonal anti-
VWF antibody (AHP062, 1:10,000) from Serotec (Kidlington, UK), rabbit
polyclonal anti-VWFpp antibody (Babich et al., 2009; Hewlett et al., 2011),
rabbit polyclonal anti-MyosinVa antibody (M4812, 1:100) from Sigma
(Gillingham, UK). Fluorophore- or horseradish-peroxidase-coupled
secondary antibodies were from Jackson ImmunoResearch Europe
(Newmarket, UK).
DNA constructs
VWFpp–EGFP, EGFP–MyRIP, EGFP–Rab27A and mRFP–Rab27A have
been described previously (Bierings et al., 2012; Hannah et al., 2005; Kiskin
et al., 2010). Flag–V159N-actin (Posern et al., 2004) was a kind gift from
Guido Posern (MLU Institute for Physiological Chemistry, Halle,
Germany). YFP–actin was from Clontech (catalogue number 6902-1).
mCherry–actin WT and mCherry–actin V159N were made by introducing a
XhoI site to the NcoI site at the N-terminus of the actin sequence using the
following polylinker: CATGGCCTCGAGGC. Actin WT or and actin
V159N were then excised using XhoI/XbaI and inserted into mCherry-C1.
MyRIP mutants were generated by site-directed mutagenesis using EGFP–
MyRIP (Bierings et al., 2012) as a template for generation of MyRIPA751P
and MyRIP 4A and MyRIP 4A as a template for MyRIP A751 4A. Primers
used had the following sequences: MYRIP A751P-f, 5′-GCCCAAGTCC-
ACCATCCTGAACTCCAGATTTCAG-3′; MYRIP A751P-r, 5′-CTGA-
AATCTGGAGTTCAGGATGGTGGACTTGGGC-3′; MYRIP RftRRR-f,
5′-CATAGCACCATGTGTGGCCTTCACAGCAGCAGCGGATCAGA-
AGCAAAGG-3′; MYRIP RftRRR-r, 5′-CCTTTGCTTCTGATCCGCTG-
CTGCTGTGAAGGCCACACATGGTGCTATG-3′.
Fluorescence microscopy
Confocal and wide-field fluorescence imaging were performed as described
previously (Bierings et al., 2012). The kinetics and extent of WPB
exocytosis in fura-2-loaded HUVECs expressing VWFpp–EGFP, EGFP–
MyRIP or EGFP–MyRIP mutants was carried out using an Olympus IX71
inverted fluorescence microscope equipped with a Olympus UPLSAPO
×100 1.40 NA objective and enclosed within a microscope incubator at
37°C as previously described (Bierings et al., 2012; Kiskin et al., 2010).
Data were acquired using the freeware software Winfluor (John Dempster,
Strathclyde University; http://spider.science.strath.ac.uk/sipbs/showPage.
php?page=software_imaging) and analysed as previously described (Erent
et al., 2007). The probability of WPB exocytosis was determined as the
mean fraction of fluorescentWPBs that underwent exocytosis following cell
stimulation, as previously described (Hewlett et al., 2011). Confocal whole
WPB bleaching and quantification of EGFP–MyRIP–WPB association
kinetics was carried out as previously described (Bierings et al., 2012). For
actin disruption, cells were treated with cytochalasin D (1 µM; 20 min). For
comparison of the exocytosis kinetics between cells expressing different
EGFP–MyRIP constructs, we selected cells with (1) similar numbers of
fluorescent WPBs and (2) similar mean WPB EGFP fluorescence
intensities. The mean WPB EGFP fluorescence intensity was determined
in ImageJ from measurements of the EGFP fluorescence intensity of 10–20
individual WPBs in each cell from wide-field live cell time-lapse videos
taken immediately prior to TIRF imaging of exocytosis. A user defined
region of interest (ROI; polygon tool in ImageJ) was drawn around each
WPB and the mean fluorescence intensity determined. The mean WPB
EGFP fluorescence intensity for a cell was determined as the mean (±s.e.m.)
of the individual WPB EGFP FI measurements made in that cell.
Single-molecule fluorescence imaging and WPB-tracking experiments
were carried out using a custom-made total internal reflection fluorescence
microscopy (TIRFM) setup. This set-up comprised a Zeiss Axiovert 135
inverted microscope (Carl Zeiss, Welwyn Garden City, UK) with an
AlphaPlan, 100×, NA1.45 objective (Carl Zeiss), and an EMCCD camera
(iXon-897BV, Andor, Belfast, UK) housed within a microscope incubator
(Solent Scientific, Segensworth, UK) at 36°C (Hern et al., 2010). Laser
excitation at 488 nm (100 mW) and 561 nm (150 mW) was provided by a
LightHUB (Omicron, Germany). To minimise false detection events during
automatic single fluorophore detection and analysis, cells expressing
EGFP–MyRIP mutants containing few or no WPBs were selected for
recording. Secretion, single-molecule or WPB-tracking data were acquired
at between 10 and 50 frames/s (as indicated in the figure legends) using
custom software and analysed using GMimPro/Motility freeware software
(Gregory Mashanov, Francis Crick Institute Mill Hill Laboratory, London,
UK, www.mashanov.uk). Estimates of the off rates for WT and mutant
MyRIP from cortical actin or stress fibres were obtained from analysis of
single EGFP fluorophore dwell times as previously described (Mashanov
et al., 2004). The automatic single particle tracking (ASPT) module in
GMimPro (Mashanov and Molloy, 2007) was used to track the x,y position
in time of WPBs expressing VWFpp–EGFP, EGFP–MyRIP or EGFP–
MyRIP mutants, yielding maximum velocities (using a seven-frame
window) and maximum displacements for individual WPBs. ASPT
settings used were FWHM500nm, R7, L100, Q10 and C3000. Data from
multiple cells for each condition were automatically pooled using Motility
software and time, x and y positions for WPBs were exported in text file
format for subsequent analysis of mean squared displacement (MSD) in
Matlab using custom-written functions. MDS plots were fitted by a
nonlinear least squares to the equation MSD(t)=A+B×tC, where A is the
offset, B is the diffusion coefficient (only correct for C=1), t is the time
interval between frames and C is the exponent, the magnitude of which gives
the general class of organelle diffusive behaviour; for free diffusion
C=1±0.2, for subdiffusive or restricted diffusion C≤0.8, and for hyper
diffusive or directed diffusion (C≥1.2). Individual data fits with an r2<0.8
were excluded from analysis. WPBs showing subdiffusive or restricted
diffusion were further fitted using equation 3 from Manneville et al. (2003)
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to determine the cage radius and cage diffusion coefficient for restricted
diffusion.
Statistical analysis
Data were plotted in Origin 9.1 or GraphPad Prism 6.0. Statistical analysis
was by t-test (non-parametric), or by one-way ANOVA using Tukey multiple
comparisons test, as indicated, and was performed with GraphPad Prism 6.0.
Significance values (P) for t-test, or multiplicity adjusted P values for
ANOVA multiple comparisons are shown in the text, on the figures or in
figure legends were appropriate. Data are shown as mean±s.e.m.
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SUPPLEMENTAL MATERIALS 
 
Supporting Fig. S1 
 
 
Fig. S1 Effect of jasplakinolide on actin cytoskeleton and cell morphology. 
S1A: Images show the effect of a 20 minute incubation with vehicle (-) or 0.1 µM to 3.0 µM 
jasplakinolide (+), as indicated, on the actin cytoskeleton and cell morphology visualised by 
expression of YFP-actin (green in colour merged images). Competitive binding of 
jasplakinolide to actin is shown by the displacement of rhodamine-phalloidin staining (red in 
colour merge images). Scale bars are 10 µm.  
 
 
 
 
 Supporting Fig. S2 
 
Fig. S2  Effect of MyRIP knockdown on WPB trafficking and VWFpp secretion. 
(Ai) Western blot showing depletion of endogenous MyRIP (top) using specific siRNA 
(siMyRIP) in HUVEC. Alpha-tubulin (-tub) controls are shown below. (Aii-iii) Confocal 
immunofluorescence image of HUVEC labelled for endogenous MyRIP (green) and VWF 
(red) in cells transfected with siControl RNA (ii) or siMyRIP RNA (iii). Greyscale images 
are from regions indicated in the colour merged panels. Scale bars are 20 µm. (B) Parameters 
determined from detected trajectories of long range movements of WPBs in HUVEC 
expressing VWFpp-EGFP and treated with siControl (black) or siMyRIP (grey) RNAi (48 
hours post transfection). Number of cells imaged and trajectories detected were: siControl, 
n=11 cells, 1470 trajectories; siMyRIP, n=12, 1324. Images were acquired at 30 frames per 
second and movements analysed in GMimPro at 10 frames per second. Comparisons by t-
test. (C) Ionomycin (1µM) stimulated secretion of endogenous VWFpp in siControl (black) 
or siMyRIP (grey) treated cells. Cells were treated with vehicle (-; RM with 0.1% DMSO) or 
cytochalasin D (+; 1µM, 20 minutes) as indicated. Plots show data from one representative 
experiment of 3 separate experiments, each performed in triplicate (mean ±s.e.m.). ANOVA, 
Tukey multiple comparisons test.  
 
  
Figure S3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S3. Time constants for EGFP-MyRIP cycling onto WPBs determined by whole 
WPB bleaching. 
Fluorescence recovery after whole WPB bleaching is due to association of new fluorescent 
molecules with WPB. Average WPB association time constants (ass) for EGFP-MyRIP 
(grey, 961.4±193.4s, n=10 WPBs, mean±SEM) or EGFP-MyRIP in the presence of co-
expressed mRFP-Rab27A (black, 1120±181.0s, n=9) determined by whole WPB FRAP. 
Green circles show the individual data points. For comparison the mean WPB association 
time constant determined previously for EGFP-Rab27A (1970±550s, n=8), and adapted from 
Fig.3D of (Bierings et al., 2012), is shown in a pale grey spot hatch.  Mean ass for EGFP-
MyRIP in the presence or absence of co-expressed mRFP-Rab27A, or for EGFP-Rab27A 
were not significantly different (ANOVA, Tukey multiple comparison test). 
 
 
 
Videos. 
Video SAi. Single molecule imaging showing EGFP-MyRIP WT binding to actin. 
Video SBi. Single molecule imaging showing EGFP-MyRIP A751P binding to actin. 
Video SCi. Single molecule imaging showing EGFP-MyRIP A4 not binding to actin. 
Video SDi. Single molecule imaging showing EGFP-MyRIP A751P A4 not binding to actin. 
 
Videos SAi-Di Single molecule TIRF imaging showing interactions of EGFP-MyRIP 
mutants with actin in live HUVEC.  
Video clips (avi format, jpg compression in ImageJ (http://rsb.info.nih.gov/ij/)) of a sub-
region of the live HUVEC co-expressing EGFP-MyRIP constructs (green) and TagRFP-actin 
(red). Videos show the dynamics of the EGFP fluorescence superimposed upon an image of 
the position of the actin cytoskeleton obtained by averaging between 401 and 900 
consecutive frames of the TagRFP channel. Video SAi: MyRIP WT, Video SBi: MyRIP 
A751P, Video SCi: MyRIP 4A, Video SDi: MyRIP A751P 4A. Videos were acquired at 50 
frames/second and time elapsed is shown. Scale bars are 10 µm. Discrete bright spots of 
EGFP fluorescence correspond to single EGFP fluorophores (Mashanov and Molloy, 2007). 
For MyRIP WT and MyRIP A751P many single EGFP fluorophores can be seen transiently 
localising to the actin cytoskeleton. For MyRIP 4A and MyRIP A751P 4A, single EGFP 
molecules do not associate with actin but remain cytosolic as a diffuse cloud of fast moving 
objects.  
 
 
 
